tumors. Prior to the acquisition of this technology by Cancer Advances, more than $230 million was spent on the development of PAS. PAS has been tested in multiple clinical trials including gastric, pancreatic, and colorectal cancer and is cleared for development in 17 North American and European countries, thereby collectively targeting a $1 billion market. In the US, gastrointestinal cancer has the second highest incidence, surpassed by only lung cancer.
About Cancer Advances
Headquartered near Research Triangle Park, privately held Cancer Advances will work with Cato Research and Cato BioVentures to develop PAS as a novel, cancer vaccine for the treatment of gastric and pancreatic cancers. Cancer Advances will announce a $50 million Series A financing opportunity at the beginning of February 2009.
About Cato Research Ltd.
Founded in 1988 by Allen Cato, M.D., Ph.D., and Lynda Sutton and headquartered near Research Triangle Park, Cato Research is a global, full-service contract research and development organization providing strategic and tactical support for clients in the pharmaceutical, biotechnology, medical device, and medical diagnostic industries. With a staff of more than 300 employees located in the United States, Europe, Canada, Israel, India, and South Africa, Cato Research's services range from design and management of preclinical and clinical studies to submission of regulatory documents required for marketing approval. For more information visit www.cato.com
About Cato BioVentures
Cato BioVentures is the venture capital affiliate of Cato Research. For nearly 20 years, Cato BioVentures has assisted entrepreneurs and established management teams in building successful life science companies. Through strategic Contract Research Organization (CRO) service agreements with Cato Research, Cato BioVentures invests Page: 1 2 3 Related biology technology :1
. Pioneering Cancer Center Introduces Advanced Varian RapidArc(TM) Treatments for Cancer Patients in Central Germany2
. Amgens Breakaway from Cancer Initiative Expands to Help Cancer Patients Access Broad Spectrum of Cancer Resources and Services3
. REXIN-G Shrinks Metastatic Tumors and Triples Survival Time in Chemotherapy-Resistant Pancreatic Cancer: Analysis of a U.S. Phase I/II Clinical Trial (Proceedings of ASCO GI Symposium 2009)4
. Introducing deCODEme Cardio(TM) and deCODEme Cancer(TM)5
. Rosetta Genomics and Collaborators Unveil Colon Cancer Screening Diagnostic; Identified Candidate MicroRNA Biomarkers in Serum6
. National Cancer Institute: Battling Cancer and a Recession7
. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer8
. Trinitas Comprehensive Cancer Center Now Offering Cancer Patients Faster, Ultra-Precise Radiation Using New RapidArc Technology9
. First Patient Dosed in Phase 2 Clinical Trial of NKTR-102 in Ovarian Cancer10
. Data Published in Nature Cell Biology Reveal Novel Function of Drug Target EpCAM in Cancer Cell Signalling11
. Genomic Health Announces Commencement of QUASAR Clinical Validation Study for Oncotype DX(R) Colon Cancer Assay